EQS-Adhoc

Tilmann Bur succeeds Gregor Siebert as CEO of PAION AG - Seite 2

Michael Schlenk, Chairman of the Supervisory Board, commented: "We would like to thank Mr. Gregor Siebert for his great commitment during his time as interim CEO of PAION and his willingness to take on responsibility with his expertise during this important phase. During this time, he has been instrumental in driving the transformation of the company. His successor Mr. Bur takes over responsibility at a point where the course has been set for the successful commercialization of our products. We intend to take advantage of Mr. Bur's international commercial experience as a pharmaceutical expert. We wish Mr. Bur good luck in the Management Board of PAION AG."

 Gregor Siebert, CEO of PAION AG, commented: "We have successfully advanced important areas in the past year and I can look forward to the future development of the company with optimism. I would like to express my heartfelt thanks to all employees and partners and will support my successor Mr. Bur during the transition phase."

 "I am looking forward to shaping PAION's future together with the entire team. We will master exciting challenges and I am convinced that we will be able to fully realize the great potential of our products," said Tilmann Bur.

 

 About PAION

PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is Byfavo (remimazolam), an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. PAION is rolling out Byfavo in selected European markets. Byfavo is partnered in multiple territories outside of Europe. Byfavo is approved in the U.S., the EU/EEA/UK, China and South Korea for procedural sedation and in the EU/EEA, Japan, the Philippines and South Korea for general anesthesia.

In addition, PAION markets two intensive care products in selected European countries: Angiotensin II (GIAPREZA), a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock, and eravacycline (XERAVA), a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.